Rosuvastatin's Effects on Liver Cancer in Mice
Author Information
Author(s): Annemilaï Tijeras-Raballand, Patricia Hainaud-Hakim, Jean-Olivier Contreres, Caroline Gest, Carole Le Henaff, Bernard I Levy, Marc Pocard, Claudine Soria, Evelyne Dupuy
Primary Institution: Institut des Vaisseaux et du Sang, Hôpital Lariboisière
Hypothesis
Can rosuvastatin reduce liver vessel anomalies and tumor growth in hepatocellular carcinoma (HCC)?
Conclusion
Rosuvastatin reduces vessel anomalies and tumor growth while prolonging survival in mice with HCC.
Supporting Evidence
- Rosuvastatin-treated mice had a median survival time of 216 days compared to 195 days for untreated mice.
- Liver weight was significantly reduced in rosuvastatin-treated mice.
- Smaller tumor nodules were observed in rosuvastatin-treated mice.
Takeaway
Rosuvastatin helps mice with liver cancer live longer and grow smaller tumors by fixing their blood vessels.
Methodology
Transgenic mice with HCC were treated with rosuvastatin, and various parameters including survival time, liver weight, and tumor nodule size were measured.
Limitations
The study was conducted in a mouse model, which may not fully replicate human HCC.
Participant Demographics
Transgenic C57Bl6/ASV-B male mice developing HCC.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website